Bacterial profile and antimicrobial sensitivity pattern of blood specimen isolates in patients with bacteremia in the intensive care unit at Dr. Soetomo Hospital

Abstract

Link of Video Abstract: https://youtu.be/2wcFE-82J2s   Background: Critically ill patients in intensive care have a higher predisposition to acquire bacterial infections in the bloodstream. Research on bacterial profiles and blood culture sensitivity patterns in bacteremia patients can provide information for the basis of diagnosis, approaches, and treatment strategies in patients. To better understand the microbial profile and pattern of antimicrobial sensitivity of blood specimen isolate among non-COVID patients in the intensive care unit, we evaluated data from medical records that included blood cultures for all participants in the intensive care unit from January 2019 to April 2022. Method: A retrospective observational study with a cross-sectional approach was conducted in the Clinical Microbiology Department and Medical Record Unit at Dr. Soetomo Hospital. Data on surgical and non-surgical noncovid patients with bacteremia in intensive care unit patients was collected from January 2019 to April 2022. The Sample was taken with a consecutive sampling technique. Results: There were 140 isolates with positive blood culture results. The most common bacteria are  coagulase-negative Staphylococcus 22 (15.7%), Acinetobacter baumanii 25 (17.9%), and Pseudomonas aeruginosa 13 (4.9%)  in surgical and non-surgical patients. Sensitivity to Gram-positive bacteria in surgical and non-surgical patients before the pandemic linezolid  75% and vancomycin 58,3%. During pandemic linezolid at 76.9% and vancomycin at 69.2%.  Sensitivity of Gram-negative bacteria in surgical patients before the pandemic was imipenem 57.1%, meropenem 57.1%, and amikacin 47.6%. During the pandemic, amikacin 73.5%, meropenem 55.1%, and imipenem 53.1%. Non-surgical patients before the pandemic gram negative sensitivity to meropenem was 100%, ceftazidime 66.7%. During the pandemic, amikacin 59.1%, and cotrimoxazole 45.5%. Conclusion: There was no difference in the surgical and non-surgical bacterial profiles before the pandemic and during the pandemic.